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Those who have urethral injury, long-distance urethral stricture, hypospadias, or epispadias need tissue
for urethral repair. Tissue engineering is one of the solutions for urethroplasty. Three components
essential for tissue engineering are cells, scaffolds, and bioactive factors. Several animal studies of tissue-
engineered urethras have been conducted and progressed to human clinical trials by 1999. These studies
have shown that the maximum distance for normal tissue regeneration in tubularized urethral
replacement with unseeded matrices is 0.5 cm. Although autologous tissue-engineered tabularized
urethras have been successful in clinical trials, this method could be an alternative treatment for urethral
reconstruction.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.1. Introduction
Thosewho have urethral injury, long-distance urethral stricture,
hypospadias, or epispadias, need tissue for urethral repair. Skin
grafts, bullock’s urethra, veins, ureters, appendix vermiformis,
fascia of the thigh, bladder mucosa, tunica vaginalis, peritoneum,
rectal mucosa, buccal mucosa, and the prepuce have been used for
this purpose.1 However, two reasons making the aforementioned
tissues unsuitable for urethroplasty are that either the surgeons did
not succeed, or the patients suffered from donor-site surgery and
even donor-site complications. Tissue engineering is one of the
solutions for urethroplasty.
What are tissue engineering and regenerative medicine? The
term tissue engineering was introduced to medicine in 1987.1
Badylak and Nerem provided a vivid description of it in 2010:
tissue engineering involves the ex vivo creation of replacement
tissues intended for subsequent in vivo implantation.2 They also
indicated that regenerative medicine emphasizes tissue replace-
ment with ex vivo manufactured products that have evolved to
include broad strategies to induce both in vivo constructive
remodeling of cell-based and cell-free scaffold materials and true
tissue regeneration.2, China Medical University
).
ciation. Published by Elsevier Taiw2. Principles of tissue engineering
Three components essential for tissue engineering are cells,
scaffolds, and bioactive factors. A normal study design for tissue
engineering is to seed cells onto scaffolds with or without bioactive
factors, which are the constructs for the experimental group. In the
control group, scaffoldswithout cells are used for comparison. All of
them are implanted in patients for later retrieval and future eval-
uation.3 Cells for tissue engineering might be stem cells (e.g.,
fertilized eggs, or embryonic, parthenogenetic, induced pluripotent
or adult stem cells.), progenitor cells (e.g., endothelial progenitor
cells), and differentiated cells (e.g., urothelial, smooth muscle, or
squamous cells). Scaffolds for tissue engineering can be classiﬁed as
natural or synthetic, and absorbable or nonabsorbable. Most scaf-
folds are absorbable. They can be synthetic or natural polymers. The
biomaterials for urethral tissue engineering in the past were all
absorbable, including synthetic polymers (aliphatic polyesters) and
natural collagens (e.g., small-intestinal submucosa, bladder-
derived acellular submucosa, acellular urethral submucosa, fore-
skin acellular matrix, or acellular arterial matrix). Bioactive factors
for tissue engineering might be growth factors, drugs, genes, gene
products, and bioreactors.
3. Maximum distance for tissue regeneration
What is the maximum distance for normal tissue regeneration?
To answer this question, Dorin et al have designed a study using
varying lengths (0.5 cm, 1 cm, 2 cm and 3 cm) of tubular scaffolds
without cells for up to 4 weeks in an in vivo rabbit model.4 Theyan LLC. Open access under CC BY-NC-ND license.
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thrograms demonstrated normal urethral calibers in the 0.5-cm
group at all time points. Evolution of a stricture was demonstrated
in the other longer grafts by 4 weeks. There were ingrowths of
urothelial cells from the anastomotic sites in all grafts at 1 week.
They concluded that 0.5 cm appeared to be the maximum defect
distance using acellular grafts that rely on native cells for tissue
regeneration.
4. Onlay versus tubularized replacement of urethras
To regenerate urethras, onlay and tubularized replacements
have been used (Fig. 1). Onlay replacement needs a healthy urethral
bed that provides healthy cells to migrate into the construct.5 The
crucial point is the width of the construct instead of the length. We
foresee successful urethroplasty using scaffolds without cells as
long as the width of the construct is < 0.5 cm.4,6 The width of the
construct can be longer than 0.5 cm if scaffolds with cells are used.
We normally use tubularized replacement to treat long-distance
urethral stricture. It can be successful if the construct is a scaffold
with enough cells. If only scaffolds are used without cells, the
maximal length for the tubularized replacement is 0.5 cm, as in the
aforementioned animal study.4
5. Cellular origin for tubularized replacements
Examples of the most common study designs for tissue-
engineered urethras can be found in studies by De Filippo et al
and Fu et al.3,7 In the latter study, scaffolds were allogeneic bladder
submucosa, and cells were autologous foreskin epidermal cells.
They compared tubular grafts at 1 month, 2 months and 6 months
using bladder submucosa with or without foreskin epidermal cells
in an in vivo rabbit model. They have concluded that acellular
bladder submucosa seeded with epidermal cells can be used for
tubularized urethral replacement without stricture. However,
unseeded tubularized bladder submucosa can lead to poor recovery
and strictures of the urethra. They have used cell-labeling tech-
niques and have found that bromodeoxyuridine stains foreskin
epidermal cells at 1 month and 2 months after grafting, but not at 6
months. Therefore, they have concluded that epithelial cells of the
graft originate and subsequently proliferate from implanted
epidermal cells, instead of extensions from surrounding transi-
tional cells.Fig. 1. Onlay and tubularized replacement used in tissue-engineered urethral
regeneration.6. Bioactive factors
Gene therapy with the vascular endothelial growth factor
(VEGF) has been used as the bioactive factor for urethral tissue
engineering. Guan et al have compared rabbit grafts after
subcutaneous implantation into nude mice for 4 weeks using
rabbit bladder urothelial cells seeded into a decellularized rabbit
artery matrix, with or without VEGF ex vivo.8 Their scaffolds were
decellularized rabbit carotid artery matrices, and cells were
rabbit bladder urothelial cells that were transfected with
a murine stem cell viruseVEGF165egreen ﬂuorescent protein
(GFP) retrovirus in the experimental group and murine stem cell
viruseGFP retrovirus in the control group. They found that
VEGF-modiﬁed cells exhibited signiﬁcantly enhanced neo-
vascularization and formation of a urethral layer compared to
GFP-modiﬁed cells. Those results indicate that VEGF gene therapy
might increase the blood supply in tissue engineering for treating
urethral damage or loss.
7. Human clinical trials
Animal studies of tissue-engineered urethras had progressed
to human clinical trials by 1999. Atala et al have reported a clin-
ical trial using unseeded bladder submucosa for onlay replace-
ment in hypospadias patients with a 75% success rate in 1999.9
Bhargava et al also have presented a clinical trial using tissue-
engineered buccal mucosa for onlay replacement in humans
with a 60% success rate in 2008.10 One of the most remarkable
clinical trials for urethral regeneration, which has yielded
important results and concepts, was a study by Raya-Rivera
et al.11 Synthetic tubularized polyglycolic acid: poly(lactide-
coglycolide acid) scaffolds were used. Both autologous bladder
smooth muscle and urothelial cells from previous urinary bladder
biopsies were harvested and expanded. Urothelial cells were
seeded onto the luminal surface and muscle cells onto the outer
surface of the tubular scaffolds. Five boys who had urethral
defects underwent urethral reconstruction with the tissue-
engineered tubularized urethras. They remained functional in
a clinical setting for up to 6 years. To the best of our knowledge,
that was the ﬁrst successful clinical trial of tubularized tissue-
engineered urethral replacement.
8. Conclusions
In conclusion, the maximum distance for normal tissue
regeneration for tubularized urethral replacement with unseeded
matrices is 0.5 cm. Although autologous tissue-engineered tubu-
larized urethras have been successful in clinical trials,
this method could be an alternative treatment for urethral
reconstruction.
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